Answers are grounded in this paper and cite their sources.
Vascular access dysfunction continues to result in substantial morbidity for chronic hemodialysis patients. Pharmacologic and molecular biologic approaches to prevention of vascular access dysfunction, if clinically successful, will be cost effective and improve quality of life for chronic dialysis patients. This review summarizes currently available information and future prospects in pharmacologic and molecular biologic approaches to preventing vascular access stenosis.
No takes yet. Share an insight, caveat, or question.
Jonathan Himmelfarb (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: